mProX™ Human SIGLEC15 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;KHOS;U2OS

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Chromophobe Renal Cell Carcinoma; Uterine Corpus Cancer

Gene ID

Human:284266

UniProt ID

Human:Q6ZMC9

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC15 is a potential target for cancer immunotherapy, specifically in colorectal cancer (CRC) and colon adenocarcinoma (COAD). In CRC, a small molecule inhibitor targeting SIGLEC15 was found to induce cell death and inhibit migration and colony formation. This inhibitor also interacted with the SIGLEC15 binding pocket, highlighting its potential as a therapeutic agent. In COAD, SIGLEC15 expression in the stromal area was associated with poor prognosis and inversely correlated with the density of CD8+ T cells. A new immune classification based on SIGLEC15 expression indicated that patients with low SIGLEC15 expression and high PD-L1 expression had the longest survival times. In non-small cell lung cancer (NSCLC), SIGLEC15 has been proposed as a biomarker and a druggable molecule. It has distinctive expression in normal tissues and a high structural similarity to PD-L1, making it a potential target for immunotherapy. In lung adenocarcinomas, SIGLEC15 expression was positively correlated with CD8+ T cell and tumor-associated macrophage infiltration. SIGLEC15+ tumor cells and TAMs were associated with an immunosuppressive tumor microenvironment and poor prognosis. Finally, in breast cancer, osteoclast-derived apoptotic bodies expressing SIGLEC15 were found to inhibit naive CD8+ T cell activation, promoting secondary metastasis. Targeting SIGLEC15 with neutralizing antibodies reduced the incidence of secondary metastases and improved survival rates in mice with advanced breast cancer bone metastasis. Overall, SIGLEC15 has implications for cancer therapy and prognosis in various types of cancer.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human SIGLEC15 Stable Cell Line (S01YF-1023-PY203). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Johnson (Verified Customer)

What is the role of SIGLEC15 in the tumor microenvironment? May 17 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

SIGLEC15 shapes a non-inflamed tumor microenvironment and is associated with the immune risk score in bladder cancer, indicating its potential as a target for immunotherapy. May 17 2023

chat Skyler Williams (Verified Customer)

How does SIGLEC15 affect tumor-associated macrophages in pancreatic cancer? Aug 10 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

SIGLEC15 amplifies the immunosuppressive properties of tumor-associated macrophages in pancreatic cancer, suggesting its role in promoting an immunosuppressive tumor microenvironment. Aug 10 2020

Published Data

Fig.1 Knockdown Siglec-15 in U2OS and KHOS cells.

The evaluation of Siglec-15 function necessitated the transfection of KHOS and U2OS cells with siRNA to ascertain the efficiency of Siglec-15 knockdown. It was observed that the expression of Siglec-15 protein was statistically significantly inhibited following the transfection with Siglec-15 siRNA (p < 0.01).

Ref: Song, Keliang, et al. "Knocking down Siglec-15 in osteosarcoma cells inhibits proliferation while promoting apoptosis and pyroptosis by targeting the Siglec-15/STAT3/Bcl-2 pathway." Advances in Medical Sciences 67.2 (2022): 187-195.

Pubmed: 35398779

DOI: 10.1016/j.advms.2022.03.001

Research Highlights

Saqif Ahmad, Mohammed. et al. "Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes." Frontiers in immunology, 2023.
Siglecs have been identified as important targets for immunotherapy in cancer. However, current checkpoint inhibitors have not been effective in treating cancer, highlighting the necessity for new therapeutics targeted at proteins like Siglec-15. At present, there is a lack of exploration into small molecule inhibitors that target Siglec-15 and their potential regulatory mechanisms involving microRNAs in the progression of colorectal cancer (CRC). Therefore, the development of a small molecule inhibitor to specifically target Siglec-15 has been elucidated.
Saqif Ahmad, Mohammed. et al. "Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes." Frontiers in immunology, 2023.
Pubmed: 37869015 DOI: 10.3389/fimmu.2023.1254911

Zhan, Weixiang. et al. "Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma." Journal of Cancer, 2023.
The novel immune checkpoint and emerging target for next-generation cancer immunotherapy, Sialic acid binding Ig-like lectin 15 (Siglec15), has been a subject of recent research. However, the significance of Siglec15 and its relation with programmed death-ligand 1 (PD-L1) in colon adenocarcinoma (COAD) is still unknown. In this study, the researchers investigated Siglec15 expression in both tumor area (TA) and stromal area (SA) and its association with tumor-infiltrating lymphocytes (TILs) in COAD and mismatch repair-proficient (MMR-p) COAD. Results showed that Siglec15 expression was notably higher in COAD tissues compared to normal tissues. Furthermore, increased Siglec15(SA) expression was linked to poor prognosis and inversely correlated with the density of CD8+TILs.
Zhan, Weixiang. et al. "Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma." Journal of Cancer, 2023.
Pubmed: 37859817 DOI: 10.7150/jca.87618